Retour

Helius Medical Technologies, Inc. Announces Pricing of $6.4 Million Public Offering

Stocks Major shareholder announcements

NEWTOWN, Pa., May 06, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced the pricing of a public offering of 804,999 shares of its Class A common stock (“Common Stock”) and 2,047,222 Pre-Funded Warrants, each to purchase one share of Common Stock, together with accompanying Series A and Series B warrants to purchase up to an aggregate of 5,704,442 shares of Common Stock. The public offering price per share of Common Stock and accompanying Series A and Series B warrants is $2.25 and the public offering price per Pre-Funded Warrant and accompanying Series A and Series B warrant is $2.249, resulting in gross proceeds of approximately $6.4 million before deducting the placement agent's fees and other estimated offering expenses. The Series A warrants to purchase up to an aggregate of 2,852,221 shares of Common Stock will have an exercise price of $2.25 per share, will be exercisable immediately following the date of issuance and will expire five years from the original issuance date. The Series B warrants to purchase up to an aggregate of 2,852,221 shares of Common Stock will have an exercise price of $2.25 per share, will be exercisable immediately following the date of issuance and will expire twelve months from the original issuance date.

GlobeNewswire Inc. • 07/05/2024 à 04:15:00
Helius Medical Technologies, Inc. Class A Common Stock (DE)
Address: 642 NEWTOWN YARDLEY ROAD
Postal Code: 18940
City: NEWTOWN
State: PA
Phone Number: 215-944-6100
Website: https://www.heliusmedical.com
Status: Active
Company Info

Helius Medical Technologies Inc is a neurotech company focused on neurological wellness. The company's purpose is to develop, license, or acquire non-invasive technologies targeted at reducing symptoms of neurological disease or trauma. The company's product, known as the Portable Neuromodulation Stimulator (PoNS), is authorized for sale in Canada as a class II, a non-implantable medical device intended for use as a short-term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury and is to be used in conjunction with supervised therapeutic exercise.

List Date2014-06-27
MarketStocks
LocalUS
Primary ExchangeXNAS
TypeCS
Currency NameUSD
CIK0001610853
Composite figiBBG006QSQYY6
Share Class figiBBG006NXG8C0
Market Cap2,358,259 USD
SIC Code3845
SIC DescriptionELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS
Total Employees22
Share Class Shares Outstanding2530000
Weighted Shares Outstanding1593418
Round Lot100
Updated date2024-05-19
Stats
Last 5 days
17-05
16-05
15-05
14-05
13-05
Last
1.5
1.545
1.58
1.575
1.695
Variance
-2.91%
-2.22%
1.28%
-12.5%
4.95%
Open
1.545
1.58
1.56
1.8
1.615
Highest
1.61
1.635
1.665
1.8
1.72
Lowest
1.607
1.635
1.66
1.8
1.711
History
PeriodVarhighestlowest
1 week
-7.12%
1.72
1.607
1 month
-70.59%
5.12
1.607
3 month
-75.86%
6.395
1.607
6 month
-77.91%
7.0699
1.607
1 year
-80.79%
8.1467
1.607
3 year
-99.79%
718.5
1.607
5 year
-99.96%
4340
1.607
10 year
-99.99%
13562.5
1.607
Stock Financials
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-11 2023-08-10 2023-11-09 UNPUB
Assets 13,755,000 10,753,000 8,854,000 UNPUB
Current Assets 13,209,000 10,265,000 8,576,000 UNPUB
Current Liabilities 1,789,000 1,524,000 1,435,000 UNPUB
Equity 6,067,000 4,572,000 3,021,000 UNPUB
Equity Attributable To Noncontrolling Interest 0 0 0 UNPUB
Equity Attributable To Parent 6,067,000 4,572,000 3,021,000 UNPUB
Liabilities 7,688,000 6,181,000 5,833,000 UNPUB
Liabilities And Equity 13,755,000 10,753,000 8,854,000 UNPUB
Noncurrent Assets 546,000 488,000 278,000 UNPUB
Noncurrent Liabilities 5,899,000 4,657,000 4,398,000 UNPUB
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-11 2023-08-10 2023-11-09 UNPUB
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow 0 0 -7,953,000 UNPUB
Net Cash Flow, Continuing 0 0 -7,953,000 UNPUB
Net Cash Flow From Financing Activities 3,209,000 2,741,000 -5,495,000 UNPUB
Net Cash Flow From Financing Activities, Continuing 3,209,000 2,741,000 -5,495,000 UNPUB
Net Cash Flow From Investing Activities -19,000 -1,000 -6,000 UNPUB
Net Cash Flow From Investing Activities, Continuing -19,000 -1,000 -6,000 UNPUB
Net Cash Flow From Operating Activities -3,190,000 -2,740,000 -2,452,000 UNPUB
Net Cash Flow From Operating Activities, Continuing -3,190,000 -2,740,000 -2,452,000 UNPUB
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-11 2023-08-10 2023-11-09 UNPUB
Comprehensive Income/Loss -2,489,000 -1,915,000 -3,472,000 UNPUB
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 UNPUB
Comprehensive Income/Loss Attributable To Parent -2,489,000 -1,915,000 -3,472,000 UNPUB
Other Comprehensive Income/Loss 5,000 -1,915,000 -3,472,000 UNPUB
Other Comprehensive Income/Loss Attributable To Parent 5,000 -267,000 191,000 UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-11 2023-08-10 2023-11-09 UNPUB
Basic Earnings Per Share 0 0 -5 UNPUB
Benefits Costs and Expenses 2,605,000 1,904,000 3,806,000 UNPUB
Cost Of Revenue 122,000 184,000 187,000 UNPUB
Costs And Expenses 2,605,000 1,904,000 3,806,000 UNPUB
Diluted Earnings Per Share 0 0 -5 UNPUB
Gross Profit -11,000 72,000 -44,000 UNPUB
Income/Loss From Continuing Operations After Tax -2,494,000 -1,648,000 -3,663,000 UNPUB
Income/Loss From Continuing Operations Before Tax -2,494,000 -1,648,000 -3,663,000 UNPUB
Income Tax Expense/Benefit UNPUB UNPUB UNPUB UNPUB
Interest Expense, Operating UNPUB UNPUB UNPUB UNPUB
Net Income/Loss -2,494,000 -1,648,000 -3,663,000 UNPUB
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 UNPUB
Net Income/Loss Attributable To Parent -2,494,000 -1,648,000 -3,663,000 UNPUB
Net Income/Loss Available To Common Stockholders, Basic -2,494,000 -1,648,000 -3,663,000 UNPUB
Operating Expenses 3,799,000 3,291,000 3,109,000 UNPUB
Operating Income/Loss -3,810,000 -3,219,000 -3,153,000 UNPUB
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 UNPUB
Preferred Stock Dividends And Other Adjustments 0 0 0 UNPUB
Revenues 111,000 256,000 143,000 UNPUB
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-12 2022-08-15 2022-11-14 2023-03-09
Assets 9,618,000 6,546,000 18,859,000 17,287,000
Current Assets 8,026,000 5,064,000 18,217,000 16,697,000
Current Liabilities 2,199,000 1,777,000 1,200,000 1,988,000
Equity 7,130,000 4,502,000 12,961,000 8,151,000
Equity Attributable To Noncontrolling Interest 0 0 0 0
Equity Attributable To Parent 7,130,000 4,502,000 12,961,000 8,151,000
Liabilities 2,488,000 2,044,000 5,898,000 9,136,000
Liabilities And Equity 9,618,000 6,546,000 18,859,000 17,287,000
Noncurrent Assets 1,592,000 1,482,000 642,000 590,000
Noncurrent Liabilities 0 0 4,698,000 7,148,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-12 2022-08-15 2022-11-14 2023-03-09
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow -4,695,000 -3,037,000 13,421,000 3,548,000
Net Cash Flow, Continuing -4,695,000 -3,037,000 13,421,000 3,548,000
Net Cash Flow From Financing Activities -17,000 637,000 17,249,000 17,869,000
Net Cash Flow From Financing Activities, Continuing -17,000 637,000 17,249,000 17,869,000
Net Cash Flow From Investing Activities 4,000 -10,000 -7,000 -11,000
Net Cash Flow From Investing Activities, Continuing 4,000 -10,000 -7,000 -11,000
Net Cash Flow From Operating Activities -4,682,000 -3,664,000 -3,821,000 -14,310,000
Net Cash Flow From Operating Activities, Continuing -4,682,000 -3,664,000 -3,821,000 -14,310,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-12 2022-08-15 2022-11-14 2023-03-09
Comprehensive Income/Loss -4,548,000 -3,459,000 -286,000 -13,335,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Comprehensive Income/Loss Attributable To Parent -4,548,000 -3,459,000 -286,000 -13,335,000
Other Comprehensive Income/Loss -202,000 351,000 744,000 737,000
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-12 2022-08-15 2022-11-14 2023-03-09
Basic Earnings Per Share -1 -1 0 -1
Benefits Costs and Expenses 4,536,000 3,929,000 1,226,000 14,859,000
Cost Of Revenue 124,000 88,000 101,000 463,000
Costs And Expenses 4,536,000 3,929,000 1,226,000 14,859,000
Diluted Earnings Per Share -1 -1 0 -1
Gross Profit 66,000 31,000 95,000 324,000
Income/Loss From Continuing Operations After Tax -4,346,000 -3,810,000 -1,030,000 -14,072,000
Income/Loss From Continuing Operations Before Tax -4,346,000 -3,810,000 -1,030,000 -14,072,000
Income Tax Expense/Benefit UNPUB UNPUB UNPUB 0
Interest Expense, Operating UNPUB UNPUB UNPUB UNPUB
Net Income/Loss -4,346,000 -3,810,000 -1,030,000 -14,072,000
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Net Income/Loss Attributable To Parent -4,346,000 -3,810,000 -1,030,000 -14,072,000
Net Income/Loss Available To Common Stockholders, Basic -4,346,000 -3,810,000 -1,030,000 -14,072,000
Operating Expenses 4,630,000 3,461,000 4,948,000 15,840,000
Operating Income/Loss -4,564,000 -3,430,000 -4,853,000 -15,516,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 0
Preferred Stock Dividends And Other Adjustments 0 0 0 0
Revenues 190,000 119,000 196,000 787,000
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-17 2021-08-12 2021-11-09 2022-03-14
Assets 14,664,000 10,717,000 7,879,000 14,102,000
Current Assets 12,863,000 8,985,000 6,238,000 12,594,000
Current Liabilities 2,534,000 2,137,000 2,642,000 2,653,000
Equity 11,898,000 8,367,000 5,037,000 11,256,000
Equity Attributable To Noncontrolling Interest 0 0 0 0
Equity Attributable To Parent 11,898,000 8,367,000 5,037,000 11,256,000
Liabilities 2,766,000 2,350,000 2,842,000 2,846,000
Liabilities And Equity 14,664,000 10,717,000 7,879,000 14,102,000
Noncurrent Assets 1,801,000 1,732,000 1,641,000 1,508,000
Noncurrent Liabilities 0 0 200,000 193,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-17 2021-08-12 2021-11-09 2022-03-14
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow 8,078,000 -3,955,000 -2,746,000 7,682,000
Net Cash Flow, Continuing 8,078,000 -3,955,000 -2,746,000 7,682,000
Net Cash Flow From Financing Activities 11,020,000 -186,000 519,000 21,126,000
Net Cash Flow From Financing Activities, Continuing 11,020,000 -186,000 519,000 21,126,000
Net Cash Flow From Investing Activities -21,000 0 -30,000 -56,000
Net Cash Flow From Investing Activities, Continuing -21,000 0 -30,000 -56,000
Net Cash Flow From Operating Activities -2,921,000 -3,769,000 -3,235,000 -13,388,000
Net Cash Flow From Operating Activities, Continuing -2,921,000 -3,769,000 -3,235,000 -13,388,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-17 2021-08-12 2021-11-09 2022-03-14
Comprehensive Income/Loss -3,490,000 -6,166,000 -4,400,000 -18,158,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Comprehensive Income/Loss Attributable To Parent -3,490,000 -6,166,000 -4,400,000 -18,158,000
Other Comprehensive Income/Loss -128,000 -6,166,000 -4,400,000 -26,000
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-17 2021-08-12 2021-11-09 2022-03-14
Basic Earnings Per Share -2 -3 -2 -7
Benefits Costs and Expenses 3,446,000 0 0 18,654,000
Cost Of Revenue 15,000 67,000 86,000 298,000
Costs And Expenses 3,446,000 6,237,000 4,482,000 18,654,000
Diluted Earnings Per Share -2 -3 -2 -7
Gross Profit 69,000 4,000 23,000 224,000
Income/Loss From Continuing Operations After Tax -3,362,000 -5,981,000 -4,687,000 -18,132,000
Income/Loss From Continuing Operations Before Tax -3,362,000 71,000 109,000 -18,132,000
Income Tax Expense/Benefit UNPUB UNPUB UNPUB UNPUB
Interest Expense, Operating UNPUB UNPUB UNPUB UNPUB
Net Income/Loss -3,362,000 -5,981,000 -4,687,000 -18,132,000
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Net Income/Loss Attributable To Parent -3,362,000 -5,981,000 -4,687,000 -18,132,000
Net Income/Loss Available To Common Stockholders, Basic -3,362,000 -5,981,000 -4,687,000 -18,132,000
Operating Expenses 3,570,000 6,170,000 4,396,000 18,366,000
Operating Income/Loss -3,501,000 -6,166,000 -4,373,000 -18,142,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 0
Preferred Stock Dividends And Other Adjustments 0 0 0 0
Revenues 84,000 71,000 109,000 522,000
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2020-05-11 2020-08-12 2020-11-12 2021-03-10
Assets 8,461,000 8,704,000 6,026,000 6,547,000
Current Assets 5,875,000 6,743,000 4,136,000 4,685,000
Current Liabilities 2,617,000 2,027,000 2,565,000 2,424,000
Equity 5,209,000 6,396,000 3,197,000 3,871,000
Equity Attributable To Noncontrolling Interest 0 0 0 0
Equity Attributable To Parent 5,209,000 6,396,000 3,197,000 3,871,000
Liabilities 3,252,000 2,308,000 2,829,000 2,676,000
Liabilities And Equity 8,461,000 8,704,000 6,026,000 6,547,000
Noncurrent Assets 2,586,000 1,961,000 1,890,000 1,862,000
Noncurrent Liabilities 0 0 264,000 252,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2020-05-11 2020-08-12 2020-11-12 2021-03-10
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow -1,109,000 908,000 -2,599,000 -2,109,000
Net Cash Flow, Continuing -1,109,000 908,000 -2,599,000 -2,109,000
Net Cash Flow From Financing Activities 2,652,000 4,075,000 0 9,638,000
Net Cash Flow From Financing Activities, Continuing 2,652,000 4,075,000 0 9,638,000
Net Cash Flow From Investing Activities -10,000 61,000 -11,000 -9,000
Net Cash Flow From Investing Activities, Continuing -10,000 61,000 -11,000 -9,000
Net Cash Flow From Operating Activities -3,751,000 -3,228,000 -2,588,000 -11,738,000
Net Cash Flow From Operating Activities, Continuing -3,751,000 -3,228,000 -2,588,000 -11,738,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2020-05-11 2020-08-12 2020-11-12 2021-03-10
Comprehensive Income/Loss -4,121,000 -3,616,000 -3,649,000 -14,327,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Comprehensive Income/Loss Attributable To Parent -4,121,000 -3,616,000 -3,649,000 -14,327,000
Other Comprehensive Income/Loss -4,121,000 -3,616,000 -3,649,000 -197,000
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2020-05-11 2020-08-12 2020-11-12 2021-03-10
Basic Earnings Per Share 0 0 0 -12
Benefits Costs and Expenses 0 0 0 -13,469,000
Cost Of Revenue 101,000 64,000 22,000 388,000
Costs And Expenses 4,209,000 3,855,000 3,791,000 -13,469,000
Diluted Earnings Per Share 0 0 0 -12
Gross Profit 106,000 69,000 109,000 273,000
Income/Loss From Continuing Operations After Tax -4,757,000 -3,361,000 -3,477,000 14,130,000
Income/Loss From Continuing Operations Before Tax 207,000 133,000 131,000 14,130,000
Income Tax Expense/Benefit UNPUB UNPUB UNPUB 0
Interest Expense, Operating UNPUB UNPUB UNPUB UNPUB
Net Income/Loss -4,757,000 -3,361,000 -3,477,000 -14,130,000
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Net Income/Loss Attributable To Parent -4,757,000 -3,361,000 -3,477,000 -14,130,000
Net Income/Loss Available To Common Stockholders, Basic -4,757,000 -3,361,000 -3,477,000 -14,130,000
Operating Expenses 4,108,000 3,791,000 3,769,000 14,659,000
Operating Income/Loss -4,002,000 -3,722,000 -3,660,000 -14,386,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 0
Preferred Stock Dividends And Other Adjustments 0 0 0 0
Revenues 207,000 133,000 131,000 661,000
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2019-05-09 2019-08-08 2019-11-12 2020-03-12
Assets 22,498,000 18,197,000 12,880,000 10,347,000
Current Assets 20,831,000 16,529,000 11,228,000 7,241,000
Current Liabilities 9,883,000 4,861,000 3,547,000 3,802,000
Equity 12,018,000 12,782,000 8,822,000 5,835,000
Equity Attributable To Noncontrolling Interest 0 0 0 0
Equity Attributable To Parent 12,018,000 12,782,000 8,822,000 5,835,000
Liabilities 10,480,000 5,415,000 4,058,000 4,512,000
Liabilities And Equity 22,498,000 18,197,000 12,880,000 10,347,000
Noncurrent Assets 1,667,000 1,668,000 1,652,000 3,106,000
Noncurrent Liabilities 0 0 511,000 710,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2019-05-09 2019-08-08 2019-11-12 2020-03-12
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow -6,921,000 -4,334,000 -5,302,000 -20,115,000
Net Cash Flow, Continuing -6,921,000 -4,334,000 -5,302,000 -20,115,000
Net Cash Flow From Financing Activities 40,000 123,000 0 1,653,000
Net Cash Flow From Financing Activities, Continuing 40,000 123,000 0 1,653,000
Net Cash Flow From Investing Activities -161,000 -43,000 -56,000 -769,000
Net Cash Flow From Investing Activities, Continuing -161,000 -43,000 -56,000 -769,000
Net Cash Flow From Operating Activities -6,800,000 -4,414,000 -5,246,000 -20,999,000
Net Cash Flow From Operating Activities, Continuing -6,800,000 -4,414,000 -5,246,000 -20,999,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2019-05-09 2019-08-08 2019-11-12 2020-03-12
Comprehensive Income/Loss 1,212,000 -310,000 -5,520,000 -10,092,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Comprehensive Income/Loss Attributable To Parent 1,212,000 -310,000 -5,520,000 -10,092,000
Other Comprehensive Income/Loss 1,212,000 -310,000 -5,520,000 -10,092,000
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2019-05-09 2019-08-08 2019-11-12 2020-03-12
Basic Earnings Per Share 0 0 0 0
Benefits Costs and Expenses 0 0 0 -8,285,000
Cost Of Revenue 236,000 212,000 89,000 846,000
Costs And Expenses 7,498,000 6,332,000 5,886,000 -8,285,000
Diluted Earnings Per Share 0 0 0 0
Gross Profit 441,000 306,000 61,000 650,000
Income/Loss From Continuing Operations After Tax 1,324,000 -186,000 -5,588,000 9,781,000
Income/Loss From Continuing Operations Before Tax 677,000 518,000 150,000 9,781,000
Income Tax Expense/Benefit UNPUB UNPUB UNPUB UNPUB
Interest Expense, Operating UNPUB UNPUB UNPUB UNPUB
Net Income/Loss 1,324,000 -186,000 -5,588,000 -9,781,000
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Net Income/Loss Attributable To Parent 1,324,000 -186,000 -5,588,000 -9,781,000
Net Income/Loss Available To Common Stockholders, Basic 1,324,000 -186,000 -5,588,000 -9,781,000
Operating Expenses 7,262,000 6,120,000 5,797,000 24,646,000
Operating Income/Loss -6,821,000 -5,814,000 -5,736,000 -23,996,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 0
Preferred Stock Dividends And Other Adjustments 0 0 0 0
Revenues 677,000 518,000 150,000 1,496,000
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB 2018-08-09 2018-11-08 2019-03-14
Assets UNPUB 17,085,000 13,311,000 27,827,000
Current Assets UNPUB 16,717,000 12,735,000 26,961,000
Current Liabilities UNPUB 29,138,000 17,768,000 17,973,000
Equity UNPUB -12,053,000 -4,457,000 9,854,000
Equity Attributable To Noncontrolling Interest UNPUB 0 0 0
Equity Attributable To Parent UNPUB -12,053,000 -4,457,000 9,854,000
Liabilities UNPUB 29,138,000 17,768,000 17,973,000
Liabilities And Equity UNPUB 17,085,000 13,311,000 27,827,000
Noncurrent Assets UNPUB 368,000 576,000 866,000
Noncurrent Liabilities UNPUB 0 0 0
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB 2018-08-09 2018-11-08 2019-03-14
Exchange Gains/Losses UNPUB 0 4,000 54,000
Net Cash Flow UNPUB 11,592,000 -3,590,000 20,021,000
Net Cash Flow, Continuing UNPUB 11,592,000 -3,594,000 19,967,000
Net Cash Flow From Financing Activities UNPUB 18,032,000 -20,000 40,028,000
Net Cash Flow From Financing Activities, Continuing UNPUB 18,032,000 -20,000 40,028,000
Net Cash Flow From Investing Activities UNPUB -172,000 -226,000 -440,000
Net Cash Flow From Investing Activities, Continuing UNPUB -172,000 -226,000 -440,000
Net Cash Flow From Operating Activities UNPUB -6,268,000 -3,348,000 -19,621,000
Net Cash Flow From Operating Activities, Continuing UNPUB -6,268,000 -3,348,000 -19,621,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB 2018-08-09 2018-11-08 2019-03-14
Comprehensive Income/Loss UNPUB -17,707,000 -4,613,000 -29,261,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest UNPUB 0 0 0
Comprehensive Income/Loss Attributable To Parent UNPUB -17,707,000 -4,613,000 -29,261,000
Other Comprehensive Income/Loss UNPUB -17,707,000 -4,613,000 -29,261,000
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB 2018-08-09 2018-11-08 2019-03-14
Basic Earnings Per Share UNPUB -1 0 UNPUB
Benefits Costs and Expenses UNPUB UNPUB UNPUB -28,145,000
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses UNPUB UNPUB UNPUB -28,145,000
Diluted Earnings Per Share UNPUB -1 0 UNPUB
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax UNPUB -17,826,000 -4,517,000 28,623,000
Income/Loss From Continuing Operations Before Tax UNPUB -17,826,000 -4,517,000 28,623,000
Income Tax Expense/Benefit UNPUB UNPUB UNPUB UNPUB
Interest Expense, Operating UNPUB UNPUB UNPUB UNPUB
Net Income/Loss UNPUB -17,826,000 -4,517,000 -28,623,000
Net Income/Loss Attributable To Noncontrolling Interest UNPUB 0 0 0
Net Income/Loss Attributable To Parent UNPUB -17,826,000 -4,517,000 -28,623,000
Net Income/Loss Available To Common Stockholders, Basic UNPUB -17,826,000 -4,517,000 -28,623,000
Operating Expenses UNPUB 11,807,000 4,890,000 27,153,000
Operating Income/Loss UNPUB -11,807,000 -4,890,000 -26,675,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic UNPUB 0 0 0
Preferred Stock Dividends And Other Adjustments UNPUB 0 0 0
Revenues UNPUB 0 0 478,000
Calendar
17 May 2024 (Time UTC) Actual Previous Consensus
★
15:30
United States
-17800.000
★
15:30
United States
-60000.000
★
15:30
United States
53700.000
★
15:30
United States
-135800.000
★★
15:30
United States
4400.000
★
15:30
United States
215400.000
★
15:30
United States
-31400.000
★
15:30
United States
62600.000
★
15:30
United States
1300.000
★
15:30
United States
-9700.000
★
15:30
United States
199600.000
★★
15:30
United States
★
15:30
United States
★
15:30
United States
★
15:30
United States
News Stream
Stocks Company Announcement
Helius Medical Technologies, Inc. to Release First Quarter 2024 Financial Results on May 13, 2024
NEWTOWN, Pa., May 10, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that the Company will release its first quarter 2024 financial results on Monday, May 13, 2024, after the market closes.
GlobeNewswire Inc. • 1w ago
Stocks Major shareholder announcements
Helius Medical Technologies, Inc. Announces Pricing of $6.4 Million Public Offering
NEWTOWN, Pa., May 06, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced the pricing of a public offering of 804,999 shares of its Class A common stock (“Common Stock”) and 2,047,222 Pre-Funded Warrants, each to purchase one share of Common Stock, together with accompanying Series A and Series B warrants to purchase up to an aggregate of 5,704,442 shares of Common Stock. The public offering price per share of Common Stock and accompanying Series A and Series B warrants is $2.25 and the public offering price per Pre-Funded Warrant and accompanying Series A and Series B warrant is $2.249, resulting in gross proceeds of approximately $6.4 million before deducting the placement agent's fees and other estimated offering expenses. The Series A warrants to purchase up to an aggregate of 2,852,221 shares of Common Stock will have an exercise price of $2.25 per share, will be exercisable immediately following the date of issuance and will expire five years from the original issuance date. The Series B warrants to purchase up to an aggregate of 2,852,221 shares of Common Stock will have an exercise price of $2.25 per share, will be exercisable immediately following the date of issuance and will expire twelve months from the original issuance date.
GlobeNewswire Inc. • 1w ago
News Product / Services Announcement
Helius Medical Technologies, Inc. Expands Stroke Clinical Program with Participation of Shepherd Center
-- Helius Medical and Shepherd Center partner on a study that aims at rehabilitating walking mobility in people recovering from stroke ---- Shepherd Center, a top neurorehabilitation hospital, is the third site in Helius’ U.S. registrational program for Portable Neuromodulation Stimulator (PoNS®) in stroke ---- The single-arm study will evaluate PoNS in treating gait and balance deficits in chronic stroke survivors ---- Regulatory submission seeking marketing authorization for stroke expected in 2025-- NEWTOWN, Pa., April 24, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced the expansion of its clinical development program for the broadening of the labeling of its marketed PoNS device to include patients recovering from stroke with the participation of Shepherd Center, under the direction of Michael Yochelson, M.D., MBA, FAAN, FAAPMR, Chief Medical Officer. Participating to the Company-sponsored single-arm study, Shepherd Center joins Brooks Rehabilitation as a third clinical site to the overall registrational program. As one of the nation’s top neurorehabilitation hospitals, Shepherd Center is known for its innovation, patient outcomes exceeding the national average, and expertise in providing world-class clinical care for people experiencing the most complex conditions, including stroke, spinal cord and brain injuries, multi-trauma, traumatic amputations, multiple sclerosis, and pain.
GlobeNewswire Inc. • 3w ago
Management Partnerships
Helius Medical Technologies, Inc. Announces Partnership with Lovell® Government Services to Expand Reach of PoNS Therapy™
-- Lovell is an approved supplier to the U.S. Department of Veterans Affairs (VA) and Department of Defense (DoD) ---- Over 28,000 cases of multiple sclerosis (MS) are reported to the VA annually -- NEWTOWN, Pa., April 03, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced it has partnered with Lovell Government Services (“Lovell”), an SBA-certified Service Disabled Veteran Owned Small Business (“SDVOSB”), to make the Company’s Portable Neuromodulation Stimulator (“PoNS®”) device available to federal healthcare systems. PoNS is indicated in the U.S. for use as a short-term treatment of gait deficit in adults with mild-to-moderate symptoms from MS when used in conjunction with physical therapy.
GlobeNewswire Inc. • 1mo ago
Calendar Calendar of Events
Helius Medical Technologies, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results
-- Company to host call at 4:30pm today -- NEWTOWN, Pa., March 28, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced results for the quarter and full year ended December 31, 2023.
GlobeNewswire Inc. • 1mo ago
News Conference Calls/ Webcasts
Helius Medical Technologies, Inc. to Release Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024
NEWTOWN, Pa., March 15, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that the Company will release its fourth quarter and full year 2023 financial results on Thursday, March 28, 2024, after the market closes.
GlobeNewswire Inc. • 2mo ago
Health Health
Helius Medical Technologies, Inc. Announces Alignment with FDA on Registrational Program for Treatment of Stroke Patients
-- Studies uses Portable Neuromodulation Stimulator (PoNS®) to evaluate cranial-nerve non-invasive neuromodulation for gait/balance deficits in stroke patients -- -- Interaction with FDA on clinical program feasibility streamlines cost and timeline and leverages trials with the Medical University of South Carolina and Brooks Rehabilitation --
GlobeNewswire Inc. • 3mo ago
Calendar Calendar of Events
Helius Booth and Special Event at APTA Combined Sections Meeting Will Highlight Physical Therapists’ Ability to Customize PoNS Therapy® to Improve Gait in People with MS
Event Appearance Caps Year of Growth: PoNS®-Trained PTs Now Found Across the United States Event Appearance Caps Year of Growth: PoNS®-Trained PTs Now Found Across the United States
GlobeNewswire Inc. • 3mo ago
News Product / Services Announcement
Helius Medical Technologies, Inc. Announces Further Expansion of Stroke Clinical Program with the Addition of Brooks Rehabilitation Hospital
-- Brooks Rehabilitation Hospital adds a second site to the registrational program in stroke, and brings the total number of patients to 100 -- -- Study uses Portable Neuromodulation Stimulator (PoNS®) to evaluate cranial-nerve non-invasive neuromodulation for gait/balance deficits in stroke patients --
GlobeNewswire Inc. • 4mo ago
News News
Wall Street Analysts Predict a 1249.93% Upside in Helius Medical Technologies, Inc. (HSDT): Here's What You Should Know
The mean of analysts' price targets for Helius Medical Technologies, Inc. (HSDT) points to a 1249.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks Investment Research • 5mo ago
See All
Related
Latest

Contactez-nous dès aujourd'hui pour découvrir comment notre solution peut vous aider à tirer parti de la puissance des données.

CONTACTER UN EXPERT